China National Nuclear Corporation has developed the full-chain technology of producing enriched target materials for the preparation of Iodine-131 through irradiation.

According to a message from China National Nuclear Corporation (CNNC) official WeChat account, under the efficient coordination of the CNNC Isotope Production Collaborative Platform, China's independent research and development of medical isotopes has achieved further success. The platform fully utilizes the group's internal collaborative innovation advantages, integrating China Institute of Atomic Energy's Nuclear-Chemical Institute, Nuclear Power Institute, CNNC Hightech Investment, and CNNC 272 Uranium Industry to overcome the technological challenges in the entire production chain of Iodine-131 target preparation for irradiation, from pre-iodine-131 nuclide preparation to reactor irradiation to radiopharmaceutical research and development, forming a complete environmentally friendly independent industry chain. In the high abundance and high purity tellurium-130 isotope preparation, the Nuclear-Chemical Institute has overcome many key technological challenges in isotope separation, oxide synthesis, purification, etc., successfully preparing tellurium-130 oxide target materials with an abundance exceeding 99% and nuclear-grade purity standards. The Nuclear-Chemical Institute, in conjunction with CNNC 272 Uranium Industry, has batch-produced tellurium isotope separation mediums, ensuring a stable supply of raw materials for tellurium isotope separation. This achievement fills the gap in domestic large-scale preparation of high-purity enriched tellurium isotopes, providing core support for China's independent and controllable high-end nuclear medical materials.